OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults
Peter Schmidt, Jean Gong, Kristin Narayan, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 5, pp. 1365-1377
Open Access | Times Cited: 5
Peter Schmidt, Jean Gong, Kristin Narayan, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 5, pp. 1365-1377
Open Access | Times Cited: 5
Showing 5 citing articles:
SA55 broadly neutralizes SARS-CoV-2 and robustly prevents viral escape by JN.1 sublineages
Longqing Shi, Anthony Bowen, Juan Han, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Longqing Shi, Anthony Bowen, Juan Han, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)
Michael G. Ison, Debra F. Weinstein, Marta Dobryanska, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 7
Open Access | Times Cited: 13
Michael G. Ison, Debra F. Weinstein, Marta Dobryanska, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 7
Open Access | Times Cited: 13
Emerging anti-spike monoclonal antibodies against SARS-CoV-2
Eloy E. Ordaya, Raymund R. Razonable
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 3, pp. 191-201
Closed Access | Times Cited: 4
Eloy E. Ordaya, Raymund R. Razonable
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 3, pp. 191-201
Closed Access | Times Cited: 4
Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate COVID-19: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron
Michael G. Ison, Myra W. Popejoy, Nikolay Evgeniev, et al.
Open Forum Infectious Diseases (2023)
Open Access | Times Cited: 6
Michael G. Ison, Myra W. Popejoy, Nikolay Evgeniev, et al.
Open Forum Infectious Diseases (2023)
Open Access | Times Cited: 6
Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages
Jean‐Sélim Driouich, Maxime Cochin, Guillaume Lingas, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 116988-116988
Open Access | Times Cited: 1
Jean‐Sélim Driouich, Maxime Cochin, Guillaume Lingas, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 116988-116988
Open Access | Times Cited: 1
